Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.

The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the intraperitoneal treatment of ...

Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...

(BUSINESS WIRE )--Pharmanovia, a global Pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the ...